SLC5A2 and cardiovascular disorder: Dapagliflozin, one of the older SGLT2 inhibitors, has been shown to significantly reduce the morbidity and mortality of cardiovascular disease in HF patients with or without DM (hazard ratio: 0.75 and 0.73 respectively) (ClinicalTrials.gov numbers: NCT03036124) (30), improve biomarkers in HF and better patients’ quality of life (ClinicalTrials.gov numbers: NCT03036124) (31).